🇺🇸 FDA

Intelligence · Clinical Pipeline

Oncology R&D Pipeline

Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Programs
5,568

Quick answer

Oncology: NovaPharmaNews indexes 5,568 oncology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Top sponsors

Page 62 of 116

  1. Olaparib, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Olaparib

    The George Institute

    Undifferentiated pleomorphic sarcoma and Dedifferentiated liposarcoma

    phase 2 small molecule active

    1 trial

  2. Olaparib, Olaparib, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Disc Medicine

    Colorectal cancer

    phase 2 small molecule active

    1 trial

  3. Oleclumab, INFLIXIMAB, IMFINZI 50 mg/mL concentrate for solution for infusion., Datopotamab deruxtecan, PACLITAXEL, Capivasertib, DS-8201a

    AstraZeneca AB

    First-line (1L) Stage IV Triple Negative Breast Cancer (TNBC) - the subtype of breast cancer characterized by a lack of tumor expression of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2.

    phase 2 small molecule active

    1 trial

  4. Olumiant 2 mg film-coated tablets, Olumiant 4 mg film-coated tablets

    Pari Pharma GmbH

    -women with an inflammatory HCA proven at histology and with at least one inflammatory HCA of more than 5 cm. -male with at least one inflammatory HCA proven at histology whatever the size and considered as non resectable by the multidisciplinary tumor board

    phase 2 small molecule active

    1 trial

  5. Olutasidenib

    RIGEL PHARMACEUTICALS INC

    Acute Myeloid Leukemia

    phase 2 small molecule active

    1 trial

  6. Olutasidenib

    RIGEL PHARMACEUTICALS INC

    Chronic Myelomonocytic Leukemia

    phase 2 small molecule terminated

    1 trial

  7. Olverembatinib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

    phase 2 small molecule completed

    1 trial

  8. Olverembatinib

    The First People's Hospital of Lianyungang

    Myeloproliferative Neoplasm

    phase 2 small molecule active

    1 trial

  9. Omacetaxine

    Teva Pharma GmbH

    Leukemia

    phase 2 small molecule terminated

    2 trials

  10. Omacetaxine

    Teva Pharma GmbH

    Acute Myelogenous Leukemia (AML)

    phase 2 small molecule terminated

    1 trial

  11. Omacetaxine mepesuccinate

    Teva Pharma GmbH

    Chronic Myeloid Leukemia

    phase 2 small molecule completed

    3 trials

  12. Omomyc

    The George Institute

    Advanced High-Grade Osteosarcoma

    phase 2 small molecule active

    1 trial

  13. Onapristone

    Context Therapeutics

    ER-positive Breast Cancer

    phase 2 small molecule terminated

    1 trial

  14. Onapristone ER

    Context Therapeutics

    Granulosa Cell Ovarian Cancer

    phase 2 small molecule completed

    1 trial

  15. OncoTICE® powder for instillation fluid for intravesical use containing 2-8 x 108 CFU Tice BCG., N-803 (NAI), OncoTICE® 2-8 x 108 vermehrungsfähige Einheiten Pulver zur Herstellung einer Suspension zur intravesikalen Instillation

    Immunitybio Ireland Limited

    Non-Muscle Invasive Bladder Cancer

    phase 2 small molecule active

    1 trial

  16. Ontruzant 420 mg powder for concentrate for solution for infusion, Oxaliplatin onkovis 5 mg/ml Konzentrat zur Herstellung einer Infusionslösung, KEYTRUDA 25 mg/mL concentrate for solution for infusion, TAXOTERE 20 mg/1 ml concentrate for solution for infusion, Oncofolic 50 mg/ml, Injektions-/Infusionslösung, 5-FU medac 50 mg/ml, Injektionslösung

    The George Institute

    HER2-positive, localized esophagogastric adenocarcinoma

    phase 2 small molecule active

    1 trial

  17. Onvansertib

    Cardiff Oncology

    Pancreatic Cancer

    phase 2 small molecule active

    1 trial

  18. Onvansertib

    Cardiff Oncology

    Metastatic Colorectal Cancer

    phase 2 small molecule active

    2 trials

  19. Onvansertib

    Cardiff Oncology

    Acute Myeloid Leukemia

    phase 2 small molecule completed

    1 trial

  20. Onvansertib

    Cardiff Oncology

    Breast Cancer

    phase 2 small molecule active

    1 trial

  21. Onvansertib

    Cardiff Oncology

    Colorectal Cancer

    phase 2 small molecule completed

    1 trial

  22. Onvansertib

    Cardiff Oncology

    Metastatic Castration-Resistant Prostate Cancer

    phase 2 small molecule completed

    1 trial

  23. Onvansertib

    Cardiff Oncology

    Small-cell Lung Cancer

    phase 2 small molecule active

    1 trial

  24. Onvansertib

    Cardiff Oncology

    Pancreatic Ductal Adenocarcinoma

    phase 2 small molecule completed

    1 trial

  25. Opevesostat, -, CABAZITAXEL , -, FLUDROCORTISONE , Olaparib, HYDROCORTISONE , DEXAMETHASONE , -, -, -, -, Olaparib, DOCETAXEL , -

    Merck Sharp and Dohme

    Metastatic castration resistant prostate cancer (mCRPC)

    phase 2 small molecule active

    1 trial

  26. Oral Encochleated Amphotericin B (CAMB)

    Matinas BioPharma Holdings

    Acute Myeloid Leukemia

    phase 2 small molecule terminated

    1 trial

  27. Oral arsenic trioxide

    The University of Hong Kong

    Acute Myeloid Leukemia

    phase 2 small molecule active

    1 trial

  28. Orelabrutinib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Follicular Lymphoma

    phase 2 small molecule active

    1 trial

  29. Orelabrutinib

    The First People's Hospital of Lianyungang

    Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

    phase 2 small molecule active

    1 trial

  30. Orelabrutinib

    The First People's Hospital of Lianyungang

    MALT Lymphoma

    phase 2 small molecule active

    1 trial

  31. Orelabrutinib

    The First People's Hospital of Lianyungang

    Marginal Zone Lymphoma(MZL)

    phase 2 small molecule active

    1 trial

  32. Orelabrutinib

    The First People's Hospital of Lianyungang

    Primary Central Nervous System Hodgkin Lymphoma

    phase 2 small molecule active

    1 trial

  33. Organoid-guided treatment

    The First People's Hospital of Lianyungang

    HER2-negative Breast Cancer

    phase 2 small molecule active

    1 trial

  34. Orgovyx 120 mg film-coated tablets

    Fondazione Telethon ETS

    Prostate Cancer

    phase 2 small molecule active

    1 trial

  35. Orteronel 300mg BID

    Takeda

    Metastatic or Advanced Non-resectable Granulosa Cell Ovarian Tumors

    phase 2 small molecule terminated

    1 trial

  36. Osimertinib + Savolitinib

    AstraZeneca

    Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  37. Osimertinib 80 mg/40 mg

    AstraZeneca

    Stage II-IIIB Non-small Cell Lung Carcinoma

    phase 2 small molecule active

    1 trial

  38. Oxaliplatin

    Regeneron UK Limited

    Colorectal Cancer

    phase 2 small molecule active

    1 trial

  39. Oxaliplatin

    Sanofi Pasteur

    Uterine Neoplasms

    phase 2 small molecule terminated

    1 trial

  40. Oxaliplatin

    Universal Integrated

    Previously Treated Metastatic Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  41. Oxaliplatin 5 mg/ml concentrate for solution for infusion, TEMOZOLOMIDE, TRAMETINIB, DISODIUM FOLINATE, Capecitabine Accord 300 mg film-coated tablets, Temozolomide SUN 5 mg hard capsules, RUCAPARIB, Mekinist 0.5 mg film-coated tablets, Temozolomide SUN 140 mg hard capsules, REGORAFENIB, Capecitabine Accord 300 mg film-coated tablets, TEMOZOLOMIDE, TEMOZOLOMIDE, Temozolomide SUN 20 mg hard capsules, RUCAPARIB, CABOZANTINIB, Capecitabine Accord 300 mg film-coated tablets, CABOMETYX 40 mg film-coated tablets,

    Bristol-Myers Squibb Australia Pty Ltd

    Pan tumor

    phase 2 small molecule active

    1 trial

  42. Oxaliplatin Kabi 5 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Leucovorin 10 mg/ml Lösung zur Injektion/ Infusion, 5-FU medac 50 mg/ml, Injektionslösung, DS-8201a

    The George Institute

    HER2 positive resectable esophagogastric adenocarcinoma

    phase 2 small molecule active

    1 trial

  43. Oxaliplatin, 5FU, leucovorin

    Hospital Authority, Hong Kong

    Biliary Cancer Metastatic

    phase 2 small molecule active

    1 trial

  44. P276-00

    Piramal Critical Care B.V.

    Melanoma

    phase 2 small molecule completed

    1 trial

  45. PACLITAXEL , BNT326, CARBOPLATIN , BNT327, PEMBROLIZUMAB , PEMETREXED

    BioNTech SE

    Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  46. PACLITAXEL , KEYTRUDA 25 mg/mL concentrate for solution for infusion, DOCETAXEL , Lenvatinib, BEVACIZUMAB , CAPECITABINE , CARBOPLATIN , FLUOROURACIL , OXALIPLATIN , GEMCITABINE , CISPLATIN , MK-7684A, Lenvatinib

    Merck Sharp and Dohme

    Advanced solid tumors

    phase 2 small molecule active

    1 trial

  47. PACLITAXEL , Lenvatinib, MK-4830, FAMOTIDINE , KEYTRUDA 25 mg/mL concentrate for solution for infusion, PARACETAMOL , IRINOTECAN , -, Lenvatinib, -, MK-2870

    Merck Sharp and Dohme

    Advanced esophageal squamous cell carcinoma

    phase 2 small molecule active

    1 trial

  48. PACLITAXEL AHCL 6 mg/ml, solution à diluer pour perfusion, Erbitux 5 mg/mL solution for infusion, CARBOPLATINE HOSPIRA 10 mg/ml, solution injectable pour perfusion

    Ningbo Cancer Hospital

    Head and neck squamous cell carcinoma

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many oncology pipeline programs are tracked?

5,568 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.